Cargando…
Adenoviral-vectored next-generation respiratory mucosal vaccines against COVID-19
The world is in need of next-generation COVID-19 vaccines. Although first-generation injectable COVID-19 vaccines continue to be critical tools in controlling the current global health crisis, continuous emergence of SARS-CoV-2 variants of concern has eroded the efficacy of these vaccines, leading t...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10172971/ https://www.ncbi.nlm.nih.gov/pubmed/37276833 http://dx.doi.org/10.1016/j.coviro.2023.101334 |
_version_ | 1785039726447689728 |
---|---|
author | Afkhami, Sam Kang, Alisha Jeyanathan, Vidthiya Xing, Zhou Jeyanathan, Mangalakumari |
author_facet | Afkhami, Sam Kang, Alisha Jeyanathan, Vidthiya Xing, Zhou Jeyanathan, Mangalakumari |
author_sort | Afkhami, Sam |
collection | PubMed |
description | The world is in need of next-generation COVID-19 vaccines. Although first-generation injectable COVID-19 vaccines continue to be critical tools in controlling the current global health crisis, continuous emergence of SARS-CoV-2 variants of concern has eroded the efficacy of these vaccines, leading to staggering breakthrough infections and posing threats to poor vaccine responders. This is partly because the humoral and T-cell responses generated following intramuscular injection of spike-centric monovalent vaccines are mostly confined to the periphery, failing to either access or be maintained at the portal of infection, the respiratory mucosa (RM). In contrast, respiratory mucosal-delivered vaccine can induce immunity encompassing humoral, cellular, and trained innate immunity positioned at the respiratory mucosa that may act quickly to prevent the establishment of an infection. Viral vectors, especially adenoviruses, represent the most promising platform for RM delivery that can be designed to express both structural and nonstructural antigens of SARS-CoV-2. Boosting RM immunity via the respiratory route using multivalent adenoviral-vectored vaccines would be a viable next-generation vaccine strategy. |
format | Online Article Text |
id | pubmed-10172971 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-101729712023-05-11 Adenoviral-vectored next-generation respiratory mucosal vaccines against COVID-19 Afkhami, Sam Kang, Alisha Jeyanathan, Vidthiya Xing, Zhou Jeyanathan, Mangalakumari Curr Opin Virol Article The world is in need of next-generation COVID-19 vaccines. Although first-generation injectable COVID-19 vaccines continue to be critical tools in controlling the current global health crisis, continuous emergence of SARS-CoV-2 variants of concern has eroded the efficacy of these vaccines, leading to staggering breakthrough infections and posing threats to poor vaccine responders. This is partly because the humoral and T-cell responses generated following intramuscular injection of spike-centric monovalent vaccines are mostly confined to the periphery, failing to either access or be maintained at the portal of infection, the respiratory mucosa (RM). In contrast, respiratory mucosal-delivered vaccine can induce immunity encompassing humoral, cellular, and trained innate immunity positioned at the respiratory mucosa that may act quickly to prevent the establishment of an infection. Viral vectors, especially adenoviruses, represent the most promising platform for RM delivery that can be designed to express both structural and nonstructural antigens of SARS-CoV-2. Boosting RM immunity via the respiratory route using multivalent adenoviral-vectored vaccines would be a viable next-generation vaccine strategy. Elsevier B.V. 2023-08 2023-05-11 /pmc/articles/PMC10172971/ /pubmed/37276833 http://dx.doi.org/10.1016/j.coviro.2023.101334 Text en © 2023 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Afkhami, Sam Kang, Alisha Jeyanathan, Vidthiya Xing, Zhou Jeyanathan, Mangalakumari Adenoviral-vectored next-generation respiratory mucosal vaccines against COVID-19 |
title | Adenoviral-vectored next-generation respiratory mucosal
vaccines against COVID-19 |
title_full | Adenoviral-vectored next-generation respiratory mucosal
vaccines against COVID-19 |
title_fullStr | Adenoviral-vectored next-generation respiratory mucosal
vaccines against COVID-19 |
title_full_unstemmed | Adenoviral-vectored next-generation respiratory mucosal
vaccines against COVID-19 |
title_short | Adenoviral-vectored next-generation respiratory mucosal
vaccines against COVID-19 |
title_sort | adenoviral-vectored next-generation respiratory mucosal
vaccines against covid-19 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10172971/ https://www.ncbi.nlm.nih.gov/pubmed/37276833 http://dx.doi.org/10.1016/j.coviro.2023.101334 |
work_keys_str_mv | AT afkhamisam adenoviralvectorednextgenerationrespiratorymucosalvaccinesagainstcovid19 AT kangalisha adenoviralvectorednextgenerationrespiratorymucosalvaccinesagainstcovid19 AT jeyanathanvidthiya adenoviralvectorednextgenerationrespiratorymucosalvaccinesagainstcovid19 AT xingzhou adenoviralvectorednextgenerationrespiratorymucosalvaccinesagainstcovid19 AT jeyanathanmangalakumari adenoviralvectorednextgenerationrespiratorymucosalvaccinesagainstcovid19 |